Pan-Lymphoid Multi gene panel
Methodology
Molecular
Test Description and clinical significance
Genes
(17 Genes) : ATM (exons 2-63), BIRC3 (exons 6-8), BTK (exons14-16), CARD11 (exons 2-8), CD79B (exons 4-5), DDX3X (exons 7-9,11,14), FBXW7 (exons 6-9), MAPK1 (exon 7), MYD88 (exons 3-5), NOTCH1 (exons 25-28, 34), PIK3CA (exons 9-11, 20-21), PIK3CD (exons 21-24), PTEN (exons 5-6, 9), PTPN6 (exons 11-12), SF3B1 (exons 13-19), TP53 (exons 2-11), XPO (exons12-13,15)
Disease:
Lymphoproliferative disorders (CLL, Waldenstrom Macroglobulinemia, etc.)
Deep next generation sequencing of gene panel for LPD detection. Next-generation sequencing (NGS) is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA. The rapid progress in next-generation sequencing technologies has significantly contributed to our knowledge of the genetic events associated with the development, progression and treatment resistance of chronic lymphocytic leukemia patients
Specimen Requirements
Collection:
Specimen should contain atleast 0.5 mL of EDTA, citrate (ACD) or Heparinized bone marrow and peripheral blood specimens
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant.Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
Blood specimens should be kept at room temperature and preferably received within 96 hours of drawing. Samples that are 4 to 7 days old should be refrigerated
CPT(s)
81450
New York Approved
NO
TAT
7 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
